Pharma doesn’t just “win” patents. It extends them—turning time into billions.
That’s the quiet engine behind a lot of today’s blockbuster economics: patent term extensions. On paper, they’re framed as a way to compensate for delays outside a company’s…
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions Read Post »
Generic drugmakers don’t “wait their turn.” They litigate their way to it.
If you’ve ever wondered how some generics hit the market fast—sometimes years before you’d expect—there’s a playbook behind the curtain. It’s not just regulatory strategy. It’…
Drug patent cliffs don’t just threaten revenue—they reshape procurement. Here’s how to win before exclusivity ends.
The industry has a familiar script: a blockbuster approaches patent loss of exclusivity, competitors line up with “me-too” launches, and…
Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
For years, “new” drug stories have been told the same way: a novel mechanism, a pivotal trial, a c…
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying Read Post »
Drug patents don’t just “add value”—they can quietly rewrite it.
In M&A, we often talk about patents the way we talk about buildings: square footage, location, and long-term utility. But drug patents behave less like real estate and more like a l…
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value Read Post »
Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …
Two clocks. One drug. And a countdown you can’t ignore.
In pharma, timing isn’t just strategy—it’s survival. The market doesn’t care how strong your science is if your exclusivity expires before your next asset is ready. And that’s why the most impor…
Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/
DrugChatter: How quickly does advil dual action work? Read Post »
Small molecules vs. biologics: the patent playbook for generics vs. biosimilars is not just different—it’s fundamentally incompatible.
If you’re building a long-term IP strategy, the biggest mistake isn’t underestimating competition. It’s assuming the …
Biopharma’s next growth cycle won’t be won in the lab—it’ll be won in the tender.
If you’re a commercial vendor selling into EU healthcare systems, you already know the headline: loss of exclusivity (LoE) is coming. What’s less obvious is how quickly…
Get new actionable insights and updates from BiotechBlog
